Evidence map›Paper›PMID 41872613›Full record

ReviewEuropean journal of clinical pharmacology2026

Innovative applications of artificial intelligence technology in pharmacometrics.

Jieren Luo, Jiesen Yu, Zihao Cai, Ling Xu, Yinghua Lv, Qingshan Zheng, Lujin Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jieren LuoCenter for Pharmacometrics, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID http://orcid.org/0000-0001-8847-8997
Jiesen Yu *Center for Pharmacometrics, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zihao CaiCenter for Pharmacometrics, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ling XuCenter for Pharmacometrics, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yinghua LvCenter for Pharmacometrics, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Qingshan Zheng *Center for Pharmacometrics, Shanghai University of Traditional Chinese Medicine, Shanghai, China. qingshan.zheng@drugchina.net.
Lujin Li *Center for Pharmacometrics, Shanghai University of Traditional Chinese Medicine, Shanghai, China. lilujin666@163.com.

Funding

National Key Research and Development Program of China 2024YFC3506600Open Research Program of the State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine LSLSKL20240203Shanghai Municipal Health Commission Smart Healthcare Special Project 2025ZHYL037
6 · The paper itself

Abstract

Pharmacometrics, as the core discipline of model-informed drug development paradigm, quantitatively characterizes drug exposure-response dynamics using mathematical models. However, its traditional methodology, represented by nonlinear mixed-effects modeling, is inherently resource-intensive and often struggles to fully capture complex biological variability. The rapid advancement of artificial intelligence technologies offers a transformative data-driven paradigm, providing superior efficiency and predictive accuracy. Yet, the artificial intelligence approaches suffer from the “black box” constraint. This review detailed the deep, complementary integration of artificial intelligence and pharmacometrics, demonstrating how this synergy is necessary to satisfy the complex, triple demands of accuracy, efficiency, and regulatory explainability. We systematically explored innovative applications across the entire pharmacometrics workflow, including model optimization, covariate screening, virtual population generation, etc. In each section, we also presented specific application cases or workflows. Furthermore, we outlined current challenges in the implementation of artificial intelligence and proposed a vision for interdisciplinary and cross-institutional collaboration.

Indexed as

Artificial IntelligenceDrug DevelopmentHumansArtificial IntelligenceMachine learningModel-informed Drug DevelopmentPharmacometrics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.